Nosocomial Pneumonia - A Drug Pipeline Analysis Report by Technavio
LONDON--(BUSINESS WIRE)--Sep 19, 2018--Technavio has announced their latest drug pipeline analysis report on . The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of nosocomial pneumonia. The report also includes a study of the pipeline molecules in various stages including, on-going clinical trials, discovery, and pre-clinical.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180919005713/en/
Technavio has published a new report on the drug development pipeline for the treatment of nosocomial pneumonia, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
Nosocomial pneumonia: An overview
Nosocomial pneumonia is an acute lower respiratory tract infection. Hospital-acquired pneumonia (HAP) or nosocomial pneumonia refers to pneumonia attracted by a patient in a hospital at least two to three days after being admitted. HAP can be caused by a variety of pathogens, including Escherichia coli, Klebsiella pneumonia, Pseudomonas aeruginosa, Staphylococcus aureus, and methicillin-resistant S.aureus (MRSA). There are two types of nosocomial pneumonia, namely ventilator-associated pneumonia and healthcare-associated pneumonia. There are numerous symptoms of nosocomial pneumonia such as common cold, sore throat, and stuffy and runny nose, cough with greenish or pus-like phlegm, fever and chills, malaise, and mild headache, loss of appetite, nausea, and shortness of breath.
According to the Centers for Disease Control and Prevention (CDC), these were 157,5000 HCAP cases reported in the US in 2011.
Nosocomial pneumonia: Segmentation of pipeline molecules
Technavio’s research segments the pipeline molecules based on different phases of drug development including, therapies employed, route of administration (RoA), mechanism of action (MoA), therapeutic modality, and the targets for the drugs under development. In the current drug pipeline, the most preferred therapeutic modality remains the small molecule, with around 64% of the pipeline molecules administered through this mode.
Between companies and institutions, companies led the drug development space for the treatment of nosocomial pneumonia. Some of the key players include Basilea, Pharmaceutica, MedImmune, Merck Sharpe & Dohme, and Spero Therapeutics.
Some of the key topics covered in the report include:
1. Scope of the Report
2. Regulatory Framework
3. Drug Development LandscapeDrugs under development
4. Drug Development StrategiesTherapies employed Route of administration Therapeutic modality Mechanism of action
5. Recruitment StrategiesGeographical coverage Recruitment status Gender Age
6. Key CompaniesType of players Company overview
7. Discontinued and Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005713/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH HOSPITALS INFECTIOUS DISEASES PHARMACEUTICAL GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 09/19/2018 02:17 PM/DISC: 09/19/2018 02:17 PM